Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from Switzerland

25 Apr 2023

Abstract excerpt

Background Increasing reports of multidrug resistance (MDR) in clinical Pseudomonas aeruginosa have led to a necessity for new antimicrobials. Ceftazidime-avibactam (CZA) is indicated for use against MDR P. aeruginosa across a broad range of infection types and particularly those that are carbapenem resistant. This study sought to determine the molecular mechanisms of CZA and imipenem (IPM)-resistance in clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotics Pharmacokinetics and Efficacy
Share to Pneumonia and Respiratory Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37180441
DOI: 10.3389/fcimb.2023.1098944

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical Pseudomonas aeruginosa isolates from SwitzerlandPMID 37180441Read ↗

Resistance to ceftazidime–avibactam and other new β-lactams in Pseudomonas aeruginosa clinical isolates: a multi-center surveillance studySemantic proximity Read ↗

Multi-omics profiling of cross-resistance between ceftazidime-avibactam and meropenem identifies common and strain-specific mechanisms in <i>Pseudomonas aeruginosa</i> clinical isolatesSemantic proximity Read ↗

Ceftazidime/avibactam resistance is associated with PER-3-producing ST309 lineage in Chilean clinical isolates of non-carbapenemase producing Pseudomonas aeruginosa.Semantic proximity Read ↗

Resistance to ceftazidime–avibactam and underlying mechanismsSemantic proximity Read ↗

Molecular Epidemiology of Infections Caused by Carbapenem-Resistant <em>Pseudomonas aeruginosa</em> and Enterobacterales and Susceptibility of Isolates to Ceftazidime-AvibactamSemantic proximity Read ↗

Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam inPseudomonas aeruginosaisolates recovered from ICU patients in Spain and Portugal depicted by WGSSemantic proximity Read ↗

Molecular characterization of resistance mechanisms in Pseudomonas aeruginosa isolates resistant to carbapenemsSemantic proximity Read ↗

Ceftazidime resistance in Pseudomonas aeruginosa is multigenic and complexSemantic proximity Read ↗

Complex pathways to ceftolozane-tazobactam resistance in clinical <i>Pseudomonas aeruginosa</i> isolates: a genomic epidemiology studySemantic proximity Read ↗

Antimicrobial Resistance Mechanisms in Carbapenem-Resistant Pseudomonas aeruginosa Clinical Strains Isolated in Shanghai, ChinaSemantic proximity Read ↗

Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosaSemantic proximity Read ↗

Phylogenomic and phenotypic profiling of carbapenem-resistant Pseudomonas aeruginosa clinical isolates reveals lineage-specific resistance mechanisms and adaptive responses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.